Atrial Fibrillation Therapeutic Pipeline Review H1 2015 Report at RnRMarketResearch.com

Share Article

RnRMarketResearch.com adds “Atrial Fibrillation – Pipeline Review, H1 2015” to its store. The report provides an overview of the Atrial Fibrillation’s therapeutic pipeline.

Atrial Fibrillation Therapeutic Pipeline Review H2 2015

Atrial Fibrillation Therapeutic Pipeline Review H2 2015

The report "Atrial Fibrillation - Pipeline Review, H2 2015" provides comprehensive information on the therapeutic development for atrial fibrillation. Atrial fibrillation is the most ordinary type of arrhythmia. Atrial fibrillation is an unbalanced heartbeat that increases the threat of stroke and heart disease. Generally, the risk of developing atrial fibrillation increases with age and with other risk factors such as diabetes, high blood pressure, and underlying heart disease. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. The complete report is available at http://www.rnrmarketresearch.com/atrial-fibrillation-pipeline-review-h1-2015-market-report.html .

It also reviews key players involved in the therapeutic development for atrial fibrillation and special features on late-stage and discontinued projects. Companies discussed in this Atrial Fibrillation Pipeline Review H2 2015 report include ARCA biopharma, Inc., Armetheon, Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, Cardiome Pharma Corp, Daiichi Sankyo Company, Limited, Gilead Sciences, Inc.m Isis Pharmaceuticals, Inc., Laboratoires Pierre Fabre SA, Nissan Chemical Industries, Ltd., Nyken BV, Otsuka Holdings Co., Ltd., Regado Biosciences, Inc., Serodus ASA, Xention Limited.

The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Order a Purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=269547 . (This is a premium report priced at US$2000 for a single user License.)

Table of Contents

List of Tables
Number of Products under Development for Atrial Fibrillation, H1 2015 10
Number of Products under Development for Atrial Fibrillation - Comparative Analysis, H1 2015 11
Number of Products under Development by Companies, H1 2015 13
Comparative Analysis by Late Stage Development, H1 2015 14
Comparative Analysis by Clinical Stage Development, H1 2015 15
Comparative Analysis by Early Stage Development, H1 2015 16
Products under Development by Companies, H1 2015 17
Products under Development by Companies, H1 2015 (Contd..1) 18
Atrial Fibrillation - Pipeline by ARCA biopharma, Inc., H1 2015 19
Atrial Fibrillation - Pipeline by Armetheon, Inc., H1 2015 20
Atrial Fibrillation - Pipeline by AstraZeneca PLC, H1 2015 21
Atrial Fibrillation - Pipeline by Bristol-Myers Squibb Company, H1 2015 22
Atrial Fibrillation - Pipeline by Cardiome Pharma Corp, H1 2015 23
Atrial Fibrillation - Pipeline by Daiichi Sankyo Company, Limited, H1 2015 24
Atrial Fibrillation - Pipeline by Gilead Sciences, Inc., H1 2015 25
Atrial Fibrillation - Pipeline by Isis Pharmaceuticals, Inc., H1 2015 26
Atrial Fibrillation - Pipeline by Laboratoires Pierre Fabre SA, H1 2015 27
Atrial Fibrillation - Pipeline by Nissan Chemical Industries, Ltd., H1 2015 28
Atrial Fibrillation - Pipeline by Nyken BV, H1 2015 29
Atrial Fibrillation - Pipeline by Otsuka Holdings Co., Ltd., H1 2015 30
Atrial Fibrillation - Pipeline by Regado Biosciences, Inc., H1 2015 31
Atrial Fibrillation - Pipeline by Serodus ASA, H1 2015 32
Atrial Fibrillation - Pipeline by Xention Limited, H1 2015 33
Assessment by Monotherapy Products, H1 2015 34
Assessment by Combination Products, H1 2015 35
Number of Products by Stage and Target, H1 2015 37
Number of Products by Stage and Mechanism of Action, H1 2015 39
Number of Products by Stage and Route of Administration, H1 2015 41
Number of Products by Stage and Molecule Type, H1 2015 43
Atrial Fibrillation Therapeutics - Recent Pipeline Updates, H1 2015 78
Atrial Fibrillation - Dormant Projects, H1 2015 90
Atrial Fibrillation - Dormant Projects (Contd..1), H1 2015 91
Atrial Fibrillation - Dormant Projects (Contd..2), H1 2015 92
Atrial Fibrillation - Dormant Projects (Contd..3), H1 2015 93
Atrial Fibrillation - Discontinued Products, H1 2015 94

Explore more reports on Cardiovascular therapeutics industry at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/womens-health-therapeutics .

About Us:
RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.

Share article on socal media or email:

View article via:

Pdf Print

Contact Author

Ritesh Tiwari
@LifeSciReports
Follow >
Sandler Research
since: 04/2014
Like >
Follow us on
Visit website